Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LK@BCCR-FP
- Development stage
- Preclinical
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
**LK@BCCR-FP** is an experimental, orally delivered nanozyme-armored probiotic platform developed for synchronous treatment of ulcerative colitis and sepsis in mouse models. It comprises *Lactobacillus kefiranofaciens* loaded with a boronic acid chitosan-modified nanozyme core and coated with a Fu brick tea polysaccharide prebiotic shell. The platform is designed to localize at inflamed colonic mucosa, scavenge reactive oxygen species, support probiotic viability and colonization, remodel gut microbial and metabolic homeostasis, restore intestinal-barrier integrity, and reduce lipopolysaccharide translocation. In DSS-induced colitis mice, it activated Nrf2-associated antioxidant signaling and reduced p53/caspase-3-associated epithelial apoptosis; in LPS-induced sepsis mice, it reduced systemic inflammatory-metabolic disturbances and extraintestinal organ injury.
- Other names
- LK@BCCR-FP
Beyond the preview
Go deeper on LK@BCCR-FP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LK@BCCR-FP.